NLM Gateway
A service of the U.S. National Institutes of Health
Your Entrance to
Resources from the
National Library of Medicine
    Home      Term Finder      Limits/Settings      Search Details      History      My Locker        About      Help      FAQ    
Skip Navigation Side Barintended for web crawlers only

Peptidomimetics of Dipeptide Amide Efflux Pump Inhibitors Potentiate the Activity of Levofloxacin in Pseudomonas aeruginosa.

LEGER R, RENAU TE, ZHANG JZ, BELEJ P, FLAMME EM, MCMILLAN W, SANGALANG J, SHE MW, YEN R, CHAMBERLAND S, GANNON CL, LOMOVSKAYA O, LEE VJ; Interscience Conference on Antimicrobial Agents and Chemotherapy.

Abstr Intersci Conf Antimicrob Agents Chemother Intersci Conf Antimicrob Agents Chemother. 2000 Sep 17-20; 40: 207.

Microcide Pharmaceuticals Inc., Mountain View, CA

In an accompanying abstract we described the identification of D-Orn-D-hPhe-3NHQ (1) as a stable, broad-spectrum efflux pump inhibitor (EPI) that potentiates the activity of levofloxacin in P. aeruginosa. Based on these results, 1 became the new lead in our campaign to evaluate the SAR of the EPIs. With this information we expanded our synthetic scope beyond the peptide backbone to include a variety of peptidomimetics, including tertiary amides, ethers, thioethers, hydroxymethylene groups and oxazoles. Overall we prepared a variety of peptidomimetics with diverse structure that potentiate the MIC of levofloxacin in P. aeruginosa 8-fold at concentrations of EPI that range from 0.625 to 20 microg/mL. The preparation and SAR of key compounds from this study are highlighted.KEYWORDS: Efflux pump inhibitors; Levofloxacin; Pseudomonas aeruginosa

Publication Types:
  • Meeting Abstracts
Keywords:
  • Dipeptides
  • Lactams
  • Microbial Sensitivity Tests
  • Ofloxacin
  • Pseudomonas aeruginosa
  • antagonists & inhibitors
  • antibiotic PS 8
Other ID:
  • GWAIDS0010357
UI: 102247855

From Meeting Abstracts




Contact Us
U.S. National Library of Medicine |  National Institutes of Health |  Health & Human Services
Privacy |  Copyright |  Accessibility |  Freedom of Information Act |  USA.gov